// App-Quantinova.ai

687 : Combination Treatment of Liver‐Targeted HBVlocked Nucleic Acid Antisense Oligonucleotide and TLR7 Agonist RO7020531 Leads to Prolonged Off‐Treatment Antiviral Effect in The AAV‐HBV Mouse Model

Researchers

Presenter

  • Julie Blaising

Principal Investigators

  • Youjun Yu

  • Xue Zhou

  • Lykke Pedersen

  • Steffen Wildum

  • Soren Ottosen

  • Cynthia Wat

  • Lu Gao

  • Henrik Mueller

Medical Centers

  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland

  • Roche Pharma Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China,

  • Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, Hørsholm, Denmark

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • RO 7020531

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved